Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Upadacitinib Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Moderate to Severe Rheumatoid Arthritis Patients in Real-World Practice (UPHOLD)

X
Trial Profile

Upadacitinib Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Moderate to Severe Rheumatoid Arthritis Patients in Real-World Practice (UPHOLD)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms UPHOLD
  • Sponsors AbbVie
  • Most Recent Events

    • 06 Jun 2024 Status changed from active, no longer recruiting to completed.
    • 15 Nov 2023 6 months interim results on the effectiveness and safety of UPA in patients with moderate/severe RA in RW clinical practice, presented at the ACR Convergence 2023
    • 25 Jan 2023 Planned primary completion date changed from 30 Apr 2024 to 15 May 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top